Creative Biolabs' lymphocyte targeted IL-2 engineering service provides custom; precision cytokine design focused on overcoming the dual liabilities of broad cell activation and limited durability that plague conventional IL-2 molecules. We provide comprehensive IL-2 mutein design and QbD-guided manufacturing, leveraging our proprietary Cis-Targeting and partial agonism technologies. Clients gain a novel IL-2 lead candidate with > 500 selectivity for beneficial CD8+ T cells, robust CD25 activity mitigation, superior T cell persistence, and the complete CMC and PK/PD data package required to accelerate transition to advanced preclinical development and lead validation.
IntroductionWhat We Can OfferWorkflowWhy Creative BiolabsCustomer ReviewsFAQsRelated ServicesContact Us
Introduction of Lymphocyte Targeted IL-2 Engineering Service
IL-2 is a potent but pleiotropic cytokine, limited by the IL-2 Paradox, where the necessary doses for Teff/NK cell activation cause high systemic activity and Treg activation (suppression). Early formats like proleukin and second-generation NKG2D conjugates addressed some issues but failed to fully decouple desirable immune activity from systemic non-specific effects (due to NK cell activation). Creative Biolabs' lymphocyte targeted IL-2 engineering service uses next-generation precision protein design to concentrate IL-2 signaling exclusively on CD8+ T cells, resulting in a superior research profile.
For an in-depth analysis of how our services can be tailored to your specific project needs, request a consultation.
Fig.1 The multifaceted role of IL-2 in the homeostasis and functional dynamics of CD56+CD3− large granular lymphocytes. 1
What We Can Offer
Customized Design-to-Preclinical Lead Service
A dedicated, end-to-end partnership from rational IL-2 mutein design to comprehensive preclinical data packages, ensuring a seamless transition from discovery to lead candidate validation.
Dual-Mechanism Engineering
Integration of CD25 affinity attenuation for robust mitigation of unwanted IL-2 activity and proprietary partial agonism for enhanced T cell persistence (TCF-1 high phenotype).
Integrated Quality and Regulatory Support
QbD-guided process development and mammalian expression (CHO/HEK) validated for robust, clinical-scale manufacturing feasibility.
Flexible Fusion Strategy
Custom conjugation services, including Fc-fusion, PEGylation, and TME-targeting scFv development to meet your specific pharmacokinetic (PK) and pharmacodynamic (PD) requirements for research models.
Lymphocyte targeted IL-2 Engineering Service at Creative Biolabs
Why Choose Us?
Key Advantages
Unique Features
Next-Generation Specificity
We move beyond the limitations of older conjugates, which still cause significant off-target-mediated activity in research models.
Signaling for Persistence
Our expertise in engineering partial agonists at the complex is proprietary. This feature is crucial for preventing T cell exhaustion in - and research, ensuring the creation of durable, long-term immune memory for in vivo studies.
Validated Structural Biology
Our understanding of the full receptor complex, including the structure and its role in non-specific cell activation, ensures our designs are fundamentally de-risked against known liabilities in preclinical studies.
To fully understand the Creative Biolabs advantage, we invite you to get a quote today.
Customer Reviews
Unparalleled CD8+ Selectivity
Using Creative Biolabs' lymphocyte targeted IL-2 engineering service in our research has significantly improved the research window of our lead cytokine, allowing us to achieve specific CD8+ expansion that was impossible with older IL-2 formats, eliminating the NK-driven confounding factors. -M. H***.
Superior T cell Persistence
Creative Biolabs' partial agonism engineering facilitated long-term TCF-1 expression, critical for CAR-T cell support, dramatically outperforming high-affinity IL-2 analogs that led to rapid T cell exhaustion. This is a game-changer for durability studies. - Dr. K. D***.
FAQs
Q: Is the partial agonism feature compatible with cell-based therapies like CAR-T cell research?
A: Absolutely. The partial agonism feature is specifically engineered to subtly attenuate STAT5 signaling. This prevents the terminal differentiation and exhaustion of T cells and promotes the critical TCF-1 stem cell-like phenotype. This leads to enhanced persistence and superior long-term activity in preclinical models when supporting CAR-T or TIL cells in vivo.
Q: What makes your CD25 mutein design superior to the older R38A and F42K variants?
A: While the historical R38A and F42K substitutions established the proof-of-concept for CD25 attenuation, Creative Biolabs utilizes proprietary structural optimization to achieve a more profound and consistent reduction in CD25 affinity, guaranteeing mitigation of non-specific activity. More importantly, we integrate this mutein with our cell-specific targeting methods.
Related Services
TAA targeted IL-2 Engineering
This strategic conjugation ensures preferential delivery of the IL-2 mutein payload directly to the disease site, significantly increasing local concentration and enhancing research efficacy while rigorously limiting systemic activity.
This platform focuses on creating IL-2 mutein conjugates designed to bind specifically to components of the extracellular matrix (ECM) within the tumor microenvironment (TME).
Creative Biolabs provides de-risked and highly specific research leads ready for advanced validation by focusing on CD25 elimination, CD8 Cis-Targeting, and partial agonism for superior persistence. Our expert team is available to guide you through selecting the ideal IL-2 engineering strategy for your specific target and research goal. Please contact us.
Reference
Muhammad, Shan et al. "Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies." Molecular cancer vol. 22,1 121. 29 Jul. 2023. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s12943-023-01826-7
Fig.1 The multifaceted role of IL-2 in the homeostasis and functional dynamics of CD56+CD3− large granular lymphocytes. 1
